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Abstract
Background: First-generation gene signatures that identify breast cancer patients at risk of recurrence are confined to
estrogen-positive cases and are driven by genes involved in the cell cycle and proliferation. Previously we induced sets of
stromal genes that are prognostic for both estrogen-positive and estrogen-negative samples. Creating risk-management
tools that incorporate these stromal signatures, along with existing proliferation-based signatures and established
clinicopathological measures such as lymph node status and tumor size, should better identify women at greatest risk for
metastasis and death.
Methodology/Principal Findings: To investigate the strength and independence of the stromal and proliferation factors in
estrogen-positive and estrogen-negative patients we constructed multivariate Cox proportional hazards models along with
tree-based partitions of cancer cases for four breast cancer cohorts. Two sets of stromal genes, one consisting of DCN and
FBLN1, and the other containing LAMA2, add substantial prognostic value to the proliferation signal and to clinical measures.
For estrogen receptor-positive patients, the stromal-decorin set adds prognostic value independent of proliferation for
three of the four datasets. For estrogen receptor-negative patients, the stromal-laminin set significantly adds prognostic
value in two datasets, and marginally in a third. The stromal sets are most prognostic for the unselected population studies
and may depend on the age distribution of the cohorts.
Conclusion: The addition of stromal genes would measurably improve the performance of proliferation-based first-
generation gene signatures, especially for older women. Incorporating indicators of the state of stromal cell types would
mark a conceptual shift from epithelial-centric risk assessment to assessment based on the multiple cell types in the cancer-
altered tissue.
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Introduction
After a decade of development and early success, the enterprise
of building gene-based classifiers for breast cancer risk assessment
is entering a period of review and integration/consolidation
[1,2,3,4,5,6,7]. Gene-based studies have delivered insights into the
complexity of breast cancer, especially the recognition that breast
cancer consists of multiple distinct diseases at the molecular level
[8], but to date the process of translating these insights into clinical
practice has been halting and incomplete [9], though gene-based
diagnostics have demonstrated sufficient value as aids to the
prognostication of early breast cancer for estrogen-positive patients
to be cleared for clinical use by the FDA [10,11] and, in the case of
the OnctotypeDX 21-gene Recurrence Score, to be approved by
ASCO and NCCN [12]. Compared to available indices and scores
such as Adjuvant! Online and the St. Gallen guidelines, gene
signatures have demonstrated greater accuracy in discriminating
‘‘good’’ from ‘‘poor’’ prognoses, at least for estrogen-positive
patients within a near-term (five year) time frame, though the
improvement over optimized clinicopathological measures or over
indices such as the Nottingham Prognostic Index may be modest
[13,14,15].
First-generation gene signatures, most prominently the Am-
sterdam70-gene, Rotterdam 76-gene, and Genome Grade Index
(GGI) [16,17,18] are driven principally by proliferation and cell-
cycle genes [19,20,21]. In fact, several of the gene signatures
become more sensitive and specific when all but the proliferation
genes are removed [22]. Moreover, in a proof of concept Haibe-
Kains and colleagues have shown that the signal in a single
proliferation gene, AURKA, performs nearly as well as several of
the best-studied gene signatures despite the fact that they are
comprised of dozens or hundreds of genes [23]. Since proliferation
genes are mostly up-regulated for estrogen-negative tumors, they
may not exhibit the variance needed to discriminate low risk from
high risk patients in this subpopulation [22,24,25].Gene signatures
that appear to apply to both estrogen-positive and estrogen-
negative subsets, for example the 3D model-based signature
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genes, one prognostic for estrogen-positive samples, the other for
those that are estrogen-negative.
In addition to prognostic and predictive gene signatures, the
principal contribution of microarray-based studies has been the
delineation of breast cancer subtypes. A consensus has emerged
that at least three subtypes exist, one that expresses markers for
estrogen receptor a, but not for HER2, one that expresses HER2,
and a residual subtype that expresses neither [28]. General
agreement as to how these subtypes might be further elaborated
has yet to emerge, though a strong case has been made that the
estrogen receptor-positive or luminal subtype can be further
divided by the expression of proliferation genes or biomarker for
proliferation such as Ki67 [18,29].
Against this backdrop, among the efforts to refine and extend
gene-based classifiers, two lines of research stand out. One involves
efforts to define subsets of estrogen-negative or HER2-positive on
the basis of sets of immune-related genes [30,31,32,33]. The
second involves stromal signatures [34,35,36,37], some of which
appear to be driven, again, largely by the proliferation signal.
Important exceptions to this include West et al.’s Desmoids-Type
Fibromatosis (DTF) signature [38,39,40] and a stromal metagene
derived by Bianchini et al. [41]. Prominent on both of these gene
lists are collagen-related genes including SPARC, CSPG2, FBLN2,
FBN1, and type-I, type-III, and type-VI collagens. The DTF
signature was devised as a proof of concept for a larger, on-going
program that exploits the mono-cellular property of soft tissue
tumors to inductively define subtypes (or states) of fibroblastic
stroma cells [38,39,42]. It is significantly prognostic of increased
survival for breast cancer [40].
From an earlier investigation of the stromal sets as prognos-
ticators of survival there is evidence that the stromal genes add
information to estrogen and proliferation expression and to such
clinical measures as lymph node involvement [43]. Specifically
N The stromal set consisting of DCN and FBLN1 adds prognostic
value for near-term events (,2.5 years) for both lymph node-
positive and lymph node–negative patients.
N This stromal-decorin set adds substantial prognostic value for
near-term events for samples both up-regulated and down-
regulated on proliferation genes.
N A second stromal set, in which LAMA2 figures prominently,
may add prognostic value to both estrogen-positive and
estrogen-negative cohorts, though for this dataset the number
of estrogen-negative samples and events is very small [44].
These initial findings suggest, on the one hand, that the stromal
sets might possibly improve the performance of first-generation,
proliferation-based gene signatures. On the other hand, these
genes might be incorporated into the definitions of sub-subtypes in
a future breast cancer typology. To establish whether the stromal
gene sets add significant independent information to the pro-
liferation signal and to clinical descriptors, we built Cox pro-
portional hazards models to investigate disease free survival as
functions of combinations of these factors. We fit these models to
the data as a whole and, separately, to estrogen-positive and
estrogen-negative patients for each of the four breast cancer
datasets listed in Table 1. In addition to the Cox regressions, we
searched for prognostic gene sets using a visualization device that
in effect builds decision trees from partitioned heatmaps of
expression values. The predictors in the Cox models, and the
partitioned gene sets in the figures, include three sets of genes
(proliferation, stromal-decorin, and stromal-laminin), along with
clinical measures, principally lymph node status and tumor size.
Estrogen Gene Set
In the effort to determine whether the stromal signal was
substantial and independent of both estrogen and proliferation
when adjusting for clinicopathological measures, we applied
univariate and multivariate Cox regression using stepwise back-
ward elimination with a inclusion cutoff of p=0.10. In two of the
four datasets estrogen receptor status is available for each patient.
For the MAINZ and STOCKHOLM cohorts only the total
number of estrogen-positive and estrogen-negative samples is
reported. In those cases, as a surrogate for estrogen-status we used
a dichotomous variable based on expression levels for the genes in
the estrogen gene set discovered by the partitioning algorithm.
That estrogen gene set, which includes ESR1, GATA3, CA12,
JMJD2B, FOXA1, TBC1D9, SLC7A8 closely matches a number of
lists reported in the literature, including, for example, the
Sensitivity to Endocrine Therapy (SET) index, a list of genes
whose expression correlates with ESR1 [45].
Proliferation Gene Set
To render proliferation as a continuous variable in the Cox
proportional hazards models we used a set of proliferation genes
we found previously [43]. The genes in this set coincide closely to
lists of proliferation and cell cycle related genes that have been
reported in several microarray-based studies of breast cancer
[18,22,25,46,47]. Genes prominent in this set include: UBE2C,
TPX2, FOXM1, BIRC5, TOP2A, and AURKA aka STK6. Of
the forty-one distinct genes in the proliferation set, all but four
belong to the list of 97 genes that define the GGI index (while one
of the remaining four is found in the less stringent version of the
GGI list) [18]. The genes in our proliferation set also constitute
a proper subset of a second proliferation list developed by Wirapati
et al. [22] using a supervised method.
Selecting Two of Four Stromal Sets as Representative
As previously reported, there are at least four stromal gene sets
[43]. Although formal tests for separation indicate that these sets
induce distinct patterns of partitions of breast cancer samples into
subgroups, a case can be made that the four can be reduced to two
pairs of sets, and, consequently, can be represented by just two of
the original sets. Specifically, the ordering induced on the breast
cancer samples by expression levels for the genes in the large
collagen set, which closely resembles West et al.’s DTF signature,
is quite similar to the ordering on the samples induced by the small
set consisting of only decorin and fibulin-1. Similarly, the two
remaining stromal sets induce similar orderings on breast cancer
samples when expression levels across the genes are ranked. These
two gene sets characterized, respectively, by LAMA2 and CAV-1,
might be jointly represented by the laminin set, which is comprised
of: LAMA2, IGF1, C10orf56, MFAP4, COL14A1, ZNF423, and
ABCA8. (It should be noted that unlike gene lists assembled on the
basis of a correlation, the ordering of the genes is not informative,
reflecting only the ordering of the probe sets on the Affymetrix
HG-U133A platform. Also, since each gene in a particular set
induces essentially the same ordering and partitioning on the
breast cancer samples, proper subsets of a gene set may be
functionally substituted for the set as a whole.).
Beyond the convenience of small size, a justification for
choosing the stromal-decorin and stromal-laminin sets is that they
are, at least in univariate models, among the most prognostic of
increased survival [43]. A second justification concerns possible
biological relevance due to biological function and cell type. That
is, it may be the case that these two sets, though related in the
pattern of partitions expressed, may reflect changes in the state of
aberration of two different cell types. The loss of decorin and
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of myoepithelial and myofibroblast cells in the case of decorin, and
of myoepithelial cells, in the case of laminin. The loss of expression
of these decorin and laminin gene sets could signal the extinction
of the myoepithelial cell layer and the de-differentiation of stromal
fibroblasts (reactive stroma). These sets may, therefore, potentially
function as markers for the state of cell types in the stromal
compartment. They might serve as indicators of the extent or
degree of tissue change reflecting progression of the disease. If this
is the case, then the choice of the stromal-decorin and stromal-
laminin sets could be justified by their potential roles as indicators
of the aberrant state of at least two cell types within the cancer-
affected tissue.
Results
Uppsala
The UPPSALA dataset as reported in [44] is a population-
based cohort of 251 consecutively presented breast cancer patients
obtained from Uppsala county, Sweden, in the years 1987 to 1989.
The Affymetrix HG-U133A expression data is available at Gene
Expression Omnibus (GEO) [48] as series GSE3494, along with
clinical descriptions, including Breast Cancer Specific Survival
events and times for 236 of the samples.
Using Kaplan-Meier product limit estimations we previously
reported that the proliferation and four stromal sets are significant
univariate predictors of disease specific survival for this cohort.
This is the case when events are censored at five and ten years, and
with full follow-up [43]. This finding prompts the question of
whether these sets remain significant in combination and in the
presence of clinicopathological parameters, such as estrogen-
status, lymph node involvement, and tumor size and grade. Of
particular interest is that the univariate results suggest that at least
one of the stromal sets, that containing LAMA2, may be prognostic
for estrogen-negative breast cancer. If this proves to be truly the
case, then stromal factors might be usefully incorporated into the
next generation of breast cancer classifiers/disagnostic functions
since first-generation signatures fail to discriminate good from
poor prognosis for women with estrogen receptor-negative disease.
Table 2 records the results from a series of univariate and
multivariate Cox models for this dataset. The object is to discern
whether the predictors in the models (rows) add independent
prognostic value for the population of samples indicated by the
columns. Several of the multivariate models appear twice, once
with one predictor in bold font and a second time with a second
predictor in bold, e.g., ‘‘proliferation + decorin’’ and ‘‘decorin
+ proliferation’’. The entries in the table are the z values of the
corresponding predictor. Z values with a p value less than 0.05
appear in bold. The purpose of the table is to provide a summary
view of the sets or clinical measures that add prognostic
information, and in which combinations, for the cohort restricted
to estrogen receptor-positive samples, and for the cohort restricted
to estrogen receptor-negative samples. Each entry in the table is
taken from a Cox proportional hazards model which is presented
in full as a table in File S1.
Focusing on the models for the estrogen-positive and estrogen-
negative subsamples the essential finding for the Uppsala cohort is
that proliferation and stromal-decorin are independently prognos-
tic for estrogen-positive tumors, but not for estrogen-negative ones,
whereas stromal-laminin is either significant or marginally
significant for the estrogen-negative subpopulation. In more detail,
for the 202 estrogen-positive samples in the Uppsala cohort, of the
four clinical measures (age, grade, tumor size and nodal status),
only size and nodal status remain significant in multivariate
models selected by backwards elimination. For these estrogen
receptor-positive samples, proliferation is prognostic at full follow-
up and with events censored at five years, as a single predictor and
in combination with stromal-decorin and with clinical variables,
but not with both. In contrast, for these estrogen receptor-positive
samples stromal-decorin is prognostic at full follow-up and with
events censored at five years, as a single predictor and in
combination with proliferation and clinical descriptors. For the 34
estrogen-receptor negative samples, only stromal-laminin is
significant, and only with censoring at five years and in
combination with clinical variables, though stromal-laminin is
marginally significant as a single predicator for full follow-up and
with events censored at five years. Among the Cox models
summarized in Table 2, the two models extracted to Tables 3 and
4 are of particular interest. The domain for the first is estrogen
receptor-positive samples, using as predictors proliferation, stro-
mal-decorin, and clinical descriptors (nodal status and tumor size).
The domain for the second is estrogen receptor-negative samples,
using as predictors proliferation, stromal-laminin and nodal status
and tumor size. The stromal sets in these two models are
significant while the proliferation set is not, as reflected in the
hazard ratios and p-values.
In summary, for the Uppsala cohort, the regressions, supple-
mented by the visual check of the partitions, provide evidence that
Table 1. Datasets.
Dataset Samples
a ER+/ER2
b Age
c LNN/LN+
d Size
e Grade
f Endpoint
g Data source rf
Uppsala 251/236 202/34 64+/214
h 158/84/9 22+/213
h 69/126/54/2 BCSS SE3494 [44]
Mainz 200/200 156/44
i 60+/212
i 200/0 21+/210
h 29/136/35/0 DMFS GSE11121 [32]
San Francisco 118/117 74/43 51+/215
h 71/66 27+/214
h 14/46/65 DMFS E-TABM-158 [50]
Stockholm 159/159 130/29 56+/214
h 94/60 22+/12
h 28/58/61/12 BCSS GSE1456 [49]
aNumber of samples/Number of samples with survival data.
bEstrogen receptor status.
cMedian age in years; mean age for Mainz.
dLymph Node status: LNN/LN+/unknown.
eAverage tumor size in cm.
fHistological Grade: 1/2/3/unknown.
gEndpoint: Breast Cancer Specific Survival, Distant Metastasis Free Survival.
hsource=[57].
iAs reported in [32], but not available in GSE11121.
doi:10.1371/journal.pone.0037646.t001
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independent predictor of disease specific survival.
N While there are too few events in the Uppsala cohort to be
confident of the pattern, visual inspection of the data suggest
that the stromal-laminin gene set may be prognostic of disease
specific survival of estrogen-negative patients, which is not the
case for the proliferation set.
Stockholm
Our first attempt to confirm the UPPSALA results on a second
dataset was somewhat disappointing. The STOCKHOLM dataset
provides evidence that stromal-decorin is prognostic for estrogen
receptor-positive samples and stromal-laminin for the estrogen
receptor-negative samples, but in both cases the association does
not reach statistical significance. The STOCKHOLM dataset
consists of 159 breast cancer patients treated at the Karolinska
Hospital between January 1994 and December 1996 [49]. As an
unselected, population-based study of Swedish women it resembles
the UPPSALA cohort. The logged and normalized Affymetrix
HG-U133A expression data is available at GEO as series
GSE1456, along with clinical descriptions (version 2, revised June
12, 2009). The GEO expression data does not include estrogen-
status, though the overall proportion of estrogen receptor-negative
samples to estrogen receptor-positive samples (29/130) can be
inferred from a summary table in the published article [49]. To
assemble ER+ and ER- groups we split the 159 samples at the 18.2
quantile using the estrogen-related gene set described earlier. As
summarized in Table 5, the same series of Cox proportional
hazards models as in the UPPSALA analysis reveals that:
N Stromal-decorin is prognostic as a univariate predictor of
disease specific survival for the dataset as a whole with full
follow-up, but only marginally so for the estrogen-receptor
positive samples, (z=21.55, 95CI 0.38–1.11, p=0.11).
N For the estrogen-negative subset only stromal-laminin is
prognostic, and then only marginally so (z=21.68, 95CI
0.1–1.18, p=0.09).
Inspecting the multivariate models for the STOCKHOLM data
there is not strong evidence that the stromal-decorin gene set adds
prognostic information to proliferation. The stromal-laminin set
may add prognostic value for estrogen-receptor negative samples,
but at a level that falls below statistical significance.
Table 2. Cox proportional hazards models for the UPPSALA cohort.
Cox proportional hazards models
Uppsala 202 ER+
full follow-up
Uppsala 202 ER+
censored@5 years
Uppsala 34 ER-
full follow-up
Uppsala 34 ER-
censored@5 years
Proliferation 3.71 3.36 1.31 0.24
proliferation + clinical 2.67 2.36 1.12
proliferation +decorin 2.17 2.15 0.43 0.69
proliferation + decorin + clinical 1.37 1.44 0.03 0.57
proliferation + laminin 2.06 2.38 20.55 20.52
proliferation + laminin + clinical 1.72 2.11 20.79 20.02
Decorin 24.36 23.75 21.73 21.19
decorin + clinical 23.65 22.89 21.56
decorin + proliferation 22.97 22.44 20.99 20.44
decorin + proliferation + clinical 22.74 22.09 21.44 21.1
laminin 23.43 22.5 21.92 21.74
laminin + clinical 22.97 21.16 21.97
laminin + proliferation 21.35 20.38 21.56 21.47
laminin + proliferation + clinical 20.53 0.47 22.09 21.77
Column labels indicate subsets of samples and follow-up period, e.g., ‘‘ER+@5’’ stands for estrogen-receptor positive samples with events censored at five years. Rows
specify the predictors in a Cox proportional hazards model. Table entries report the z value of the first predictor of the model in the corresponding row for the samples
in the corresponding column. Entries with p-values less than 0.05 appear in bold.
doi:10.1371/journal.pone.0037646.t002
Table 3. Multivariate Cox proportional hazards model with stromal-decorin for UPPSALA estrogen receptor-positive samples.
UPPSALA estrogen receptor-positive samples (n=202) with full follow-up
log(HR) HR Z p 95CI-lower 95CI-upper
nodal status 1.15 3.17 3.755 0.0001 1.73 5.8
tumor size 0.02 1.02 2.324 0.02 1.004 1.05
proliferation 0.38 1.46 1.37 0.17 0.84 2.53
stromal-decorin 20.67 0.5 22.748 0.005 0.31 0.82
likelihood ratio test=47, 4 df, p=1.41E-09
doi:10.1371/journal.pone.0037646.t003
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and STOCKHOLM, might be ascribed to differences in the
number of samples or to the composition of the samples in terms of
clinical descriptors. With only 130 and 29 samples in the ER+ and
ER2 groups, it could well be the case that the multivariate Cox
proportional hazards models built for the STOCKHOLM cohort
lack the statistical power to discern the relationship between the
stromal sets and proliferation observed in the UPPSALA data.
Alternatively, or in addition, though in both UPPSALA and
STOCKHOLM studies patients were accrued consecutively and
in an unselected manner from the population, a comparison of the
clinical descriptions of the women may show a bias, e.g.,
a disproportionate number of older or more progressed cases.
With this possibility in mind, we investigated the association
between the stromal gene sets and clinical descriptors in the
UPPSALA data. Of the five clinical variables available (histologic
grade, ER-status, PgR-status, age, lymph node-status and tumor
size) after backward elimination only lymph node-status and tumor
size remained significant in the multivariate Cox models with
proliferation and stromal-decorin or stromal-laminin (File S1).
Lymph Node-status
Investigating the association between stromal set expression and
lymph node status in the estrogen receptor-positive and estrogen
receptor-negative subcohorts in the UPPSALA data, it is amply
clear that the stromal sets add prognostic value to lymph node-
status. This is visibly apparent in Figure 1 which arranges the
UPPSALA patients by lymph node- and estrogen-status, then
orders the samples by stromal-laminin expression. As evidenced by
how the attached Disease Specific Survival events (censored at 2.5
and 5 years) cluster at the low end of stromal-laminin expression, it
would appear that stromal-laminin adds considerable prognostic
information to lymph node-status, in particular to the subset of
samples that are lymph node-positive. The same is the case for
stromal-decorin. If the prognostic value of the stromal sets depend
on the presence (and relative proportion) of lymph node-positive
samples in a dataset, then the discrepancy in the results between
the UPPSALA and STOCKHOLM cohorts might be explained
by a difference in the proportion of lymph node-positive patients.
Unfortunately, though the overall number of lymph node-positive
samples in the UPPSALA dataset can be inferred from a summary
table in [49], the lymph node status of the individual samples is not
supplied in the public version of the dataset.
Table 4. Multivariate Cox proportional hazards model with stromal-laminin for UPPSALA estrogen receptor-negative samples.
UPPSALA Estrogen receptor-negative samples (n=34) with full follow-up
log(HR) HR Z p 95CI-lower 95CI-upper
nodal status 1.2 3.33 1.23 0.21 0.48 22.8
tumor size 0.05 1.06 0.915 0.36 0.93 1.2
proliferation 21.71 0.17 20.797 0.42 0.008 12.26
stromal-laminin 22.6 0.07 22.099 0.03 0.006 0.84
likelihood ratio test=8.58, 4 df, p=0.07
doi:10.1371/journal.pone.0037646.t004
Table 5. Cox proportional hazards models for the STOCKHOLM cohort.
Stockholm
130ER+ full
Stockholm
130ER+ @5
Stockholm29
ER- full
Stockholm 29
ER- @5
proliferation 3.46 2.79 0.83 0.75
proliferation + clinical 2.29 1.81 0.61 0.104
proliferation + decorin 3.14 2.78 20.76 0.49
proliferation + decorin + clinical 2.01 1.87 20.31 0.13
proliferation + laminin 2.6 2.1 20.64 20.34
proliferation + laminin + clinical 1.73 1.35 20.76 20.54
decorin 21.55 20.88 20.85 20.608
decorin + clinical 21.11 20.44 20.71 20.54
decorin + proliferation 0.83 1.08 21.26 20.02
decorin + proliferation + clinical 0.38 0.77 20.9 20.24
laminin 22.39 21.91 21.68 21.32
laminin + clinical 21.5 21.21 21.26 21.05
laminin + proliferation 0.23 0.15 21.73 21.22
laminin + proliferation + clinical 0.004 20.03 21.43 21.14
Column labels indicate subsets of samples and follow-up period, e.g., ‘‘Stockholm130ER+@5’’ stands for estrogen-receptor positive samples with events censored at five
years. Rows specify the predictors in a Cox proportional hazards model. Table entries report the z value of the first predictor of the model in the corresponding row for
the samples in the corresponding column. Entries with p-values less than 0.05 appear in bold.
doi:10.1371/journal.pone.0037646.t005
Stromal Signal Is Independent of Proliferation
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e37646Pursuing the notion that the prognostic value of the stromal sets
might be confined to lymph node-positive samples, we examined
two additional datasets, SAN FRANCISCO [50] and MAINZ
[32], selected because they differ substantially in the proportion of
lymph node positive tumors, one with an abundance of lymph
node positive samples, and a second with none at all. For both of
these cohorts we built the same series of Cox proportional hazards
models as for the UPPSALA and STOCKHOLM data.
San Francisco
The third dataset consists of 118 tumor samples collected at the
University of California San Francisco and Pacific Medical Center
between 1989 and 1997 [50]. It is enriched in lymph node-positive
samples (66 of 118), and in comparison to the UPPSALA cohort
contains a greater proportion of samples with larger tumor size
and higher histologic grade. The Affymetrix HG-U133A expres-
sion data is downloadable from ArrayExpress [51], accession
number E-TABM-158. One sample lacks Distant Metastasis Free
Survival (DMFS) event and time, leaving 117 samples for survival
analysis. Under backwards elimination with a cutoff p-value of 0.1,
none of the clinical predictors (age, nodal-status, histologic grade,
tumor size or sizing) proved significant in multivariate models. The
Cox models summarized in Table 6 show that:
N Stromal-decorin is a significant predictor in multivariate
models with proliferation for the the estrogen receptor-positive
subset with full follow-up and with dmfs events censored at five
years.
N The stromal-laminin gene set is prognostic as a single predictor
for the estrogen-positive subset with full follow-up.
N None of the three gene sets, proliferation, stromal-decorin, or
stromal-laminin, is prognostic for the estrogen receptor-
negative cohort, in either univariate or multivariate models.
Essentially the SAN FRANCISCO data confirms the finding in
UPPSALA regarding the prognostic value of stromal-decorin for
estrogen receptor-positive subcohort, but it does not confirm the
finding regarding the value of stromal-laminin for the estrogen
receptor-negative sub-cohort.
Mainz
Further pursuing the possible association between the prognos-
tic value of the stromal sets and lymph node-status, to set up
a contrast with the SAN FRANCISCO data, we built our series of
Cox models for a dataset in which the samples are exclusively
lymph node-negative. Like the UPPSALA cohort, the 200 samples
in the MAINZ dataset represent a population-based consecutive
series, in this case accrued at Mainz between 1988 and 1998 [32].
The normalized Affymetrix HG-U133A expression data is avail-
able at GEO as series GSE11121, which includes clinical variables
for histological grade and tumor size, but not for estrogen-status,
though the overall proportion of estrogen-negative to estrogen-
positive patients is reported in the original article: (44 (22%)
estrogen-negative and 156 (78%) estrogen-negative. To form the
estrogen receptor-positive and estrogen receptor-negative subpo-
pulations we ordered the samples on the estrogen-related gene set,
dividing at the 22
nd quantile. The endpoint for this dataset was
Distant Metastasis Free Survival. The results for the MAINZ data,
as summarized in Table 7, show that:
N For the estrogen receptor-positive subset, stromal-decorin adds
independent prognostic information to proliferation with dmfs
events censored at five years, and marginally with full follow-
up.
N For the estrogen receptor-negative subset, stromal-laminin in
combination with proliferation is prognostic of dmfs with
events censored at five years and for full follow-up.
Figure 1. Uppsala samples partitioned by lymph node status and estrogen-status, ordered on stromal-laminin gene expression.
Yellow signifies up-regulation; blue signifies down-regulation. Rows represent probe sets on the Affymetrix HG U133A platform. Black bars record
Breast Cancer Specific Survival events censored at 2.5 years. Blue bars record BCSS events that occur between 2.5 and 5 years.
doi:10.1371/journal.pone.0037646.g001
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lymph node-negative, suggests strongly that the prognostic value of
the stromal sets is not confined to lymph node-positive tumors.
Therefore, the contrast in the results for the UPPSALA and
STOCKHOLM cohorts is likely due to some other factor.
Comparing the clinical descriptions of the samples in the four
datasets, the most striking difference is the distribution of patients
by age, as tabulated in Table 8. The principal contrast is between
the UPPSALA and MAINZ cohorts, with median age of 64 and
mean age of 60, respectively, and the STOCKHOLM and SAN
FRANCISCO datasets, with median ages of 56 and 51. Also
telling is the fact that 46% of the SAN FRANCISCO patients are
50 years of age or younger and perhaps premenopausal. The
proportion of younger and premenopausal women in the
STOCKHOLM dataset cannot be determined, but, given the
median age of those patients, is perhaps significantly larger than in
the UPPSALA cohort where only 22% are less than fifty years of
age. Hence, the difference in results for UPPSALA compared to
STOCKHOLM may be attributed to the larger proportion of
older women in the UPPSALA cohort. If the stromal sets are
prognostic for older women but not for younger, this would
account for a separate finding reported in [43], namely that the
Table 6. Cox proportional hazards models for the SAN FRANCISCO cohort.
SanFrancisco74
ER+full
SanFrancisco74
ER+@5
SanFrancisco43
ER- full
SanFrancsico43
ER-@5
proliferation 2.29 1.19 0.24 0.76
proliferation + clinical
proliferation + decorin 1.77 0.82 20.09 0.86
proliferation + decorin + clinical
proliferation + laminin 0.89 0.29 0.608 0.51
proliferation + laminin + clinical
decorin 22.92 22.23 20.88 0.37
decorin + clinical
decorin + proliferation 22.54 22.08 20.86 0.54
decorin + proliferation + clinical
laminin 22.7 21.65 0.62 20.87
laminin + clinical
laminin + proliferation 21.93 21.28 0.84 20.69
Column labels indicate subsets of samples and follow-up period, e.g., ‘‘SanFrancisco74ER+@5’’ stands for estrogen-receptor positive samples with events censored at
five years. Rows specify the predictors in a Cox proportional hazards model. Table entries report the z value of the first predictor of the model in the corresponding row
for the samples in the corresponding column. Entries with p-values less than 0.05 appear in bold.
doi:10.1371/journal.pone.0037646.t006
Table 7. Cox proportional hazards models for the MAINZ cohort.
Cox proportional hazards models
Mainz 156
ER+ full
Mainz 156
ER+ @5
Mainz 44
ER- full
Mainz 44
ER- @5
proliferation 4.22 5.3 2.68 2.65
proliferation + clinical 3.19 4.32
proliferation + decorin 2.86 3.61 2.33 2.51
proliferation + decorin + clinical 2.33 3.16
proliferation + laminin 3.09 3.68 3.24 3.28
proliferation + laminin + clinical 2.43 3.21
decorin 22.87 23.38 21.27 21.04
decorin + clinical 22.31 22.77
decorin + proliferation 21.67 22.32 0.33 0.63
decorin + proliferation + clinical 21.57 22.03
laminin 22.23 22.63 21.27 20.01
laminin + clinical 21.77 22.09
laminin + proliferation 20.56 21.06 1.99 2.18
laminin + proliferation + clinical 20.63 20.79
Column labels indicate subsets of samples and follow-up period, e.g., ‘‘Mainz156ER+@5’’ stands for estrogen-receptor positive samples with events censored at five
years. Rows specify the predictors in a Cox proportional hazards model. Table entries report the z value of the first predictor of the model in the corresponding row for
the samples in the corresponding column. Entries with p-values less than 0.05 appear in bold.
doi:10.1371/journal.pone.0037646.t007
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[52], which has a median age of 49, with 76% younger than 55,
and only 1% older than 70, as reported in [32].
To test whether the prognostic value of the stromal sets is
dependent on age, we split the UPPSALA cohort at age sixty and
built Cox proportional hazards models to test the two propositions:
1. That the stromal-decorin gene set adds prognostic information
to proliferation for estrogen receptor-positive women with
invasive breast cancer.
2. That the stromal-laminin gene set is prognostic for estrogen
receptor-negative women with invasive breast cancer.
For the estrogen receptor-positive women the models recorded
in Table 9 show that stromal-decorin is significantly prognostic
independently of proliferation for the older women (.60 years) in
the UPPSALA dataset, but not for the younger women (,60
years). Testing the second proposition regarding the prognostic
value of stromal-laminin for estrogen receptor-negative women in
the UPPSALA cohort is a challenge given the small number of
samples and events. Nevertheless, there is slight evidence that
stromal-laminin is prognostic for the older women, but not for the
younger (Table 10).
Summarizing results across the four datasets:
N In three of the four cohorts (UPPSULA, SAN FRANCISCO,
and MAINZ), for estrogen-positive patients the stromal-
decorin gene set adds independent prognostic information in
multivariate models that include proliferation expression and
clinicopathological variables.
N In two datasets (UPPSALA and MAINZ) and marginally in
a third (STOCKHOLM), for estrogen-negative patients the
stromal-laminin gene set adds prognostic value.
These results may be conditioned on age, holding for older, but
not younger women.
Discussion
The expression of the genes in the stromal-decorin and stromal-
laminin sets appear to be switch-like. For the women most at risk
of metastasis and death the expression of these genes is essentially
absent. Why decorin expression is lost is unknown, but like the loss
of laminin and caveolin expression, it may stem from changes in,
and ultimately from the extinction of, the myoepithelial cell layer.
As SAGE studies of cell type and cell state document, laminin and
caveolin are lost first. Whereas laminin and caveolin are expressed
by normal myoepithelial cells, and subsequently lost by DCIS-
involved myoepithelial cells, the reverse is the case for decorin.
That is, DCN is expressed by the cancer-transformed myoepithelial
cells, and not by the normal [53,54]. The up-regulation of decorin
might be part of a stromal host response similar to foreign body
response which deposits a wall of ECM around an offending
object. If that defensive response succeeds in encapsulating the
tumor while still small, the tumor may never attain detectable size
[55]. In that case the myoepithelial layer remains intact, serving
not only as a physical barrier with the BM (the first line of defense),
but continuing to produce, in sync with fibroblasts, the right
mixture of matricellular proteins, fibrillar collagens, etc. needed for
the dynamic maintenance of the second line of defense, the
interstitial ECM reinforced by the host stromal response. The loss
of the myoepithelial layer might sufficiently alter the mix of gene
expression and products such that, the continuing desmoplastic
reaction assembles an inferior decorin-deficient matrix. The
consequence is that what had functioned as a barrier and
container is progressively transformed into a gateway and
facilitating substrate for the advancing vanguard of infiltrating
Table 8. Age distribution for five datasets.
dataset accession samples median age*
,=50
years
UPPSALA GSE3494 251 64+214 22%
MAINZ GSE11121 200 60+/212 35%
STOCKHOLM GSE1456 159 56+/214 NA
SAN FRANCISCO E-TABM-158 118 51+/215 46%
TRANSBIG GSE7390 198 46+/27 69%
Median age for UPPSALA, STOCKHOLM, SAN FRANCISCO, and TRANSBIG
cohorts. Mean age for MAINZ. Percentage of samples 50 years of age or
younger. Source for median ages=[57]. Source for percentage samples less
than 51=[58].
doi:10.1371/journal.pone.0037646.t008
Table 9. Cox proportional hazards models for UPPSALA
estrogen receptor-positive older (.60) and younger (,60)
women.
HR 95CI(lower-upper) z score p value
proliferation 2.27 0.91–5.65 1.76 0.07
stromal-decorin 0.48 0.25–0.91 22.22 0.02
Likelihood Ratio Test=9.51, 2 df, p=0.008
HR 95CI(lower-upper) z score p value
proliferation 2.19 0.63–7.61 1.24 0.35
stromal-decorin 0.57 0.17–1.86 20.92 0.35
Likelihood Ratio Test=5.94, 2 df, p=0.05
Upper model: UPPSALA estrogen receptor-positive, older women (.60 years of
age) n=117, 19 Breast Cancer Specific Survival events censored @ 5 years.
Lower model: UPPSALA estrogen receptor-positive, younger women (,60 years
of age) n=83, 13 Breast Cancer Specific Survival events censored @ 5 years.
doi:10.1371/journal.pone.0037646.t009
Table 10. Cox proportional hazards models for UPPSALA
estrogen receptor-negative older (.60) and younger (,60)
women.
HR 95CI(lower-upper) z score p value
stromal-
laminin
0.084 0.008–0.88 22.06 0.03
Likelihood Ratio Test=6.37, 1 df, p=0.01
HR 95CI(lower-upper) z score p value
stromal-
laminin
2.13 0.13–34.4 0.53 0.59
Likelihood Ratio Test=0.28, 1 df, p=0.59
Upper model: UPPSALA estrogen receptor-negative, older women (.60 years
of age) n=20, 3 Breast Cancer Specific Survival events censored @ 5 years.
Lower model: UPPSALA estrogen receptor-negative, younger women (,60
years of age) n=10, 1 Breast Cancer Specific Survival event censored @ 5 years.
doi:10.1371/journal.pone.0037646.t010
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indicator and causal factor of this change.
As we have been most recently reminded by A. Bergamaschi
(personal communication), physiological differences in the struc-
ture and stiffness of breast tissue is associated with aging. Here at
the intersection of the biology of tumor progression and the
biology of ageing, an emerging message from the data analysis is
that the protective value of the expression of the stromal sets holds
for older women, but not for younger. That is, older women with
breast cancer who are capable of mounting a robust stromal
response are those who are most likely to survive their disease.
Monitoring that response as mirrored in the expression of the
stromal-decorin and stromal-laminin sets may be strategic for
patient management in this cohort.
After a decade of development, there has been an increasingly
urgent call for gene signatures that do not rely exclusively on
proliferation to discriminate good from poor prognosis [22].
Incorporating the stromal sets takes a step in a direction which
may lead to a signature that is both grounded in the biology of the
disease and more accurate in identifying patients at greatest risk.
Materials and Methods
The stromal and proliferation gene sets used as predictors in the
multivariate Cox proportional hazards models were induced by
the partition-based algorithm described in [43] as applied to the
Uppsala dataset [44]. For the derivation of the gene sets with
a worked example, see Supplemental Methods in File S2, which
describes instances of the stromal-decorin gene set (Table S1) and
of all gene sets detected in the UPPSALA data (Table S2).
Univariate and multivariate Cox proportional hazards models
with combinations of gene sets and clinicopathological measures
were built using the coxph function in the r survival package [56]
using backward elimination with a p-value cutoff of 0.1 applied to
the Affymetrix HG-U133A expression data for four breast cancer
datasets designated as: UPPSALA [44], MAINZ [32], SAN
FRANCISCO [50], and STOCKHOLM [49]. The full de-
scription and result for each model is tabulated in File S1.
To visually inspect the prognostic value of the stromal genes in
combination with proliferation genes and lymph node status we
partitioned and stacked heatmaps to provide the equivalent of
binary decision trees. These were programmed in Java by the
author.
Supporting Information
Table S1 An Excel workbook that records the gene sets detected
by the partition-based algorithm applied to the UPPSALA data
with partition size=129, and tolerance for mismatch=17.
(XLS)
Table S2 An Excel workbook that records all of the gene sets
detected in the UPPSALA data.
(XLS)
File S1 An Excel workbook with twenty-four spread sheets
which record Cox proportional hazards models (six worksheets for
each of four datasets). Each sheet contains six to twelve or more
models grouped by domain (all samples, estrogen-positive samples,
estrogen-negative samples) and by follow-up (censored at five years
and full follow-up).
(XLS)
File S2 Supplemental Methods. A Word document that
describes the derivation of the gene sets.
(DOC)
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